Golden State Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Golden State Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$101K	Sell	227 -23	-9%	-$10.7K	0.01%	519
2025 Q4	$113K	Sell	250 -15	-6%	-$6.46K	0.01%	497
2025 Q3	$104K	Buy	265 +9	+4%	+$3.76K	0.01%	496
2025 Q2	$114K	Buy	256 +161	+169%	+$74.2K	0.01%	452
2025 Q1	$46.1K	Buy	95 +4	+4%	+$1.86K	0.01%	611
2024 Q4	$36.6K	Buy	+91	New	+$42.2K	0.01%	639
2022 Q1	–	Sell	-961	Closed	-$211K	–	368
2021 Q4	$211K	Buy	+961	New	+$187K	0.04%	347
2021 Q3	–	Sell	-1,065	Closed	-$215K	–	328
2021 Q2	$215K	Buy	+1,065	New	+$223K	0.05%	273
2020 Q2	–	Sell	-71	Closed	-$17K	–	898
2020 Q1	$17K	Buy	+71	New	+$16.3K	0.01%	533
2019 Q4	–	Sell	-71	Closed	-$12K	–	936
2019 Q3	$12K	Hold	71	–	–	﹤0.01%	720
2019 Q2	$13K	Hold	71	–	–	﹤0.01%	704
2019 Q1	$13K	Buy	+71	New	+$13.1K	﹤0.01%	725

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Golden State Wealth Management's VRTX Position: Q1 2026 in Review

Golden State Wealth Management reduced its Vertex Pharmaceuticals (VRTX) stake by 9.2% in Q1 2026, selling an estimated $10.7K and leaving 227 shares worth $101K. The position accounts for 0.01% of the portfolio, ranked #519.

Golden State Wealth Management first reported a position in VRTX in Q1 2019 and has held it in 12 quarters since. The position peaked at $215K in Q2 2021. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Golden State Wealth Management held 227 shares of Vertex Pharmaceuticals worth $101K as of Q1 2026.
Golden State Wealth Management sold 23 Vertex Pharmaceuticals shares in Q1 2026, an estimated $10.7K.
Vertex Pharmaceuticals made up 0.01% of Golden State Wealth Management's portfolio in Q1 2026, its #519 holding.
Golden State Wealth Management first reported a position in Vertex Pharmaceuticals in Q1 2019 and has held it in 12 quarters since.
Golden State Wealth Management's Vertex Pharmaceuticals position peaked at $215K in Q2 2021.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Golden State Wealth Management's 13F filing for Q1 2026, filed 28 Apr 2026.